Filing Details
- Accession Number:
- 0001415889-25-003824
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-02-12 21:30:01
- Reporting Period:
- 2025-02-10
- Filing Date:
- 2025-02-12
- Accepted Time:
- 2025-02-12 21:30:01
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1438533 | Travere Therapeutics Inc. | TVTX | Pharmaceutical Preparations (2834) | 262383102 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1698262 | E. William Rote | C/O Travere Therapeutics, Inc. 3611 Valley Centre Drive, Ste 300 San Diego CA 92130 | Senior Vice President, R&D | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-02-10 | 8,000 | $0.00 | 103,719 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-02-12 | 5,200 | $23.53 | 98,519 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Performance-based restricted stock units | Disposition | 2025-02-10 | 8,000 | $0.00 | 8,000 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | M | Direct |
Footnotes
- On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 8,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain clinical/regulatory performance criteria. On February 10, 2025, the PSUs vested upon the Issuer's confirmation that the clinical/regulatory performance criteria had been satisfied, including confirming a path forward for submitting an sNDA for traditional approval of FILSPARI (sparsentan) in FSGS.
- Each PSU represents a contingent right to receive one share of the common stock of the Issuer.
- This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of the PSUs.
Billionaire Hedge Funds
